SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aphton (apht) -- Ignore unavailable to you. Want to Upgrade?


To: Henry Volquardsen who wrote (87)3/31/1999 1:33:00 PM
From: mason630  Read Replies (1) | Respond to of 95
 
I've been a shareholder since 94 with an average buy price of 17. It's good to see the price inching back up there. Aphton achieved another milestone today with their news release announcing "Clinical Proof of Concept in Prostate Cancer Patients. . . " That means their Gonadimmune (now called GnRH pharmaccine by SKB) works! I think this is exciting. I wonder when the Morgan Stanley Dean Witter brokers will get involved in the stock.